Buybacks / stock splits / share capital changes • NVIDIA $NVDAB : Added a $150 billion buyback. • Hesai Technology (NASDAQ: HSAI): The board authorized a $100 million buyback program to repurchase Class B ordinary shares and/or ADSs over the 12 months from 11/18; repurchased shares are expected to be cancelled. CEO Yifan Li said it demonstrates confidence in the business outlook. • Baidu (NASDAQ: $BIDU.US ): Repurchased 568,400 ADSs on 11/18 for approximately $5 million; cumulative repurchases since authorization total 12,412,500 shares (0.454% of shares outstanding). • Innoviz (NASDAQ: $INVZ): Announced a 1-for-20 reverse stock split, with authorized share capital correspondingly reduced from 500 million shares to 25 million shares (announced 11/18). 6. FDA approvals / clinical data / pharmaceuticals (a flurry of developments on 11/18) • Bayer — Sunharbo (asundexian): FDA approved this first factor XIa inhibitor to reduce stroke risk in patients who recently experienced a mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. Based on the Phase 3 OCEANIC-STROKE trial of over 12,000 people, adding it to antiplatelet therapy reduced ischemic stroke by 26% compared with antiplatelet therapy alone; major bleeding was 1.9% vs. 1.7%. Priced at $748.50 for 30 days. The approval paves the way for pipeline competitors such as milvexian and abelacimab. • Sanofi ($Sanofi) — Infilbray (venglustat): FDA approved it for neurological symptoms of type 3 Gaucher disease, making it the first therapy for neurological symptoms of the disease; it can cross the blood-brain barrier. Based on the 43-person, randomized, double-blind LEAP2MONO trial, it showed improvement in ataxia and cognitive assessments compared with enzyme replacement therapy. Approved one week ahead of the 11/25 target date; it has orphan drug and priority review designations. • $GSK.US — Nelkarmi (neladalkib): FDA granted accelerated approval to this next-generation selective ALK TKI for locally advanced or metastatic ALK-positive non-small cell lung cancer following treatment with other ALK inhibitors. Based on the Phase I/II ALKOVE-1 trial (ORR 49%/32%). The asset originated from GSK’s $10.6 billion acquisition of Nuvalent this year, and is the second oncology drug approved following the acquisition; Jefferies estimates peak sales of Nuvalent’s three drugs could reach $5–7 billion.